Get all premium features to the best stock analysis tool

Ocumetics Completes Manufacturing of Next Generation Solid State Accommodating Intraocular Lenses for Upcoming Group Two First in Human Clinical Surgeries

Key Highlights Next-generation Ocumetics Lenses successfully manufactured and ready for the Company's upcoming Group Two first-in-human clinical surgeries in Mexico City.

Ocumetics Announces Completion of Third and Final Tranche of Unit Private Placement

Calgary, Alberta – TheNewswire - August 24, 2026 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the third and final tranche of the private placement previously announced by the Corporation on July 7, July 29, July 30, 2026 and July 31, 2026 (the “ Offering ”).   The Corporation has issued an additional 405,000 units (“ Units ”) at a price of $0.40 per unit for aggregate gross proceeds of $162,000.  Each Unit consists of one common share in the share capital of the Corporation (“ Common Share ”) and one common share purchase warrant (“ Warrant ”).  Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.50 for a period of three years from the date of issuance of the Warrant.

Ocumetics Announces Completion of Second Tranche of Unit Private Placement

Calgary, Alberta – July 31, 2026 – TheNewswire -  Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the second tranche of the private placement previously announced by the Corporation on July 7, July 29 and July 30, 2026 (the “ Offering ”).   The Corporation has issued an aggregate of 6,250,000 units (“ Units ”) at a price of $0.40 per unit for aggregate gross proceeds of $2,500,000.  Each Unit consists of one common share in the share capital of the Corporation (“ Common Share ”) and one common share purchase warrant (“ Warrant ”).  Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.50 for a period of three years from the date of issuance of the Warrant.